Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

REACTIVITY SENSITIVITY MW (kDa) SOURCE
H Endogenous 50, 60 Rabbit

Western blot analysis of extracts from COS cells transfected with human ECGF1 using TP/ECGF1 Antibody.

Learn more about how we get our images

Western blot analysis of extracts from human THP-1 cells, untreated or LPS-treated overnight, using TP/ECGF1 Antibody.

Learn more about how we get our images
Image

Product Usage Information

Application Dilutions
Western Blotting 1:1000

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

TP/ECGF1 Antibody detects endogenous levels of human TP/ECGF1 protein.


Species Reactivity: Human

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding residues surrounding Gln370 of human TP/ECGF1. Antibodies are purified by peptide affinity chromatography.

Thymidine phosphorylase (TP) is a platelet-derived endothelial cell growth factor (PD-ECGF) that catalyzes the formation of thymine and 2-deoxy-D-ribose-1-phosphate from thymidine and orthophosphate (1). This intracellular enzyme is capable of both promoting angiogenesis and inhibiting apoptosis. Thymidine phosphorylase catalytic activity is required for its angiogenic function (2,3). Increased expression of TP/PD-ECGF is seen in a wide variety of different solid tumors and inflammatory diseases and is often associated with poor prognosis (4,5). Alternatively, TP can activate fluorouracil derivative (DFUR) prodrugs and increase the antitumor activity of the related treatment (1,5). The use of thymidine phosphorylase as a cancer therapeutic target has been studied extensively, with emphasis on either inhibiting TP enzymatic activity or increasing enzyme induction with concomitant DFUR treatment (1,5).


1.  Rooseboom, M. et al. (2004) Pharmacol Rev 56, 53-102.

2.  Moghaddam, A. and Bicknell, R. (1992) Biochemistry 31, 12141-6.

3.  Furukawa, T. et al. (1992) Nature 356, 668.

4.  Toi, M. et al. (2005) Lancet Oncol 6, 158-66.

5.  Liekens, S. et al. (2007) Biochem Pharmacol 74, 1555-67.


Entrez-Gene Id 1890
Swiss-Prot Acc. P19971


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.